Jan. 22, 2013
-based Tethys Bioscience, developers of the PreDx® test, the predictive multi-biomarker blood test that differentiates adults with prediabetes according to their 5-year likelihood of progressing to type 2 diabetes, enabling clinicians to focus additional attention on those at highest imminent risk of disease conversion.
Congresswoman Lee, who has been a strong advocate of biotechnology and medical innovation throughout her 8 terms in Congress, toured the Tethys Clinical Laboratory, where the PreDx test was developed and where over 150,000 PreDx tests have been processed since its commercial launch in 2008. In her comments to Lab personnel, Congresswoman Lee praised the important work that Tethys has done to enable the more effective prevention of type 2 diabetes, which has reached epidemic levels throughout
the United States
and within the local community.
"Tethys' work to identify and more effectively treat patients at the highest risk for type 2 diabetes is a welcome step forward in our shared mission to reduce the prevalence of this preventable disease," said Congresswoman
. "Type 2 diabetes, among other health conditions, remains widespread among low-income communities and communities of color, and I am optimistic that this work will lead to healthier families and communities in the Bay Area and across the country."
About Congresswoman Barbara Lee
Congresswoman Lee represents the new 13th Congressional District of California. During the 113th Congress, Rep. Lee will continue to serve on the House Appropriations Committee and will also serve on the House Budget Committee and the Steering and Policy Committee. She will continue to work to lift millions of Americans out of poverty, eradicate healthcare disparities, ensure that our country's budget is both fair and balanced, and to invest in the future of all Americans.